Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2005
05/18/2005CN1617711A Liposomal delivery of vitamin E based compounds
05/18/2005CN1617704A Composition comprising at least one oxazolin for inhibiting langerhans cell migration, and uses thereof
05/18/2005CN1617691A Prevention and treatment of androgen-deprivation induced osteoporosis
05/18/2005CN1616386A Intermediate for preparing isothiazole derivatives
05/18/2005CN1616104A Transfusion medicine prepared from xylitol as istonic regulator and various injections separately and its preparing method
05/18/2005CN1616102A Compound dry suspensoid agent for curing cold and its prescription and preparing method
05/18/2005CN1616101A Novel medicine for treating malaria controlling malaria spreading
05/18/2005CN1616100A Beta-lactam antibiotic compound oral preparation and its preparing method
05/18/2005CN1616099A Anti-cancer medicine composition
05/18/2005CN1616098A Anti-cancer medicine composition
05/18/2005CN1616084A Botulinum toxin pharmaceutical compositions
05/18/2005CN1615907A Carbon gas gel transfusion agent, its preparing method and its use
05/18/2005CN1615893A Prescription of compound skeletal musle relaxant and analgesic containing etezamide and its preparing method
05/18/2005CN1615892A Prescription of compound antipyretic analgesic containing etenzamide and its preparing method
05/18/2005CN1615891A Compound and use for the treatment of benign prostatic hyperplasia and relative diseases
05/18/2005CN1615880A Combined agents for treatment of glaucoma
05/18/2005CN1615879A Combined agents for treatment of glaucoma
05/18/2005CN1201821C Stable complex of insoluble chemical compound
05/18/2005CN1201820C Compositions containing benzimidazolones and progestogens
05/18/2005CN1201814C Treatment of cardiao megaly
05/18/2005CN1201812C Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor
05/18/2005CN1201730C Treatment of emphysema using RAR selective retinoid agonists
05/18/2005CN1201728C Incorporation of active substances in carrier matrixes
05/17/2005US6894157 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
05/17/2005US6894058 Administering statin drug
05/17/2005US6894050 3,4,5,6-tetrahydro-2h-(1,2')bipyrazinyl derivatives
05/17/2005US6894047 Triazine compounds useful as sorbitol dehydrogenase inhibitors
05/17/2005US6894038 Administering an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for treating multiple sclerosis
05/17/2005US6894033 Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
05/17/2005US6894030 Treatment of DNA viral infections
05/17/2005US6894028 Use of KPV tripeptide for dermatological disorders
05/17/2005US6894027 Stimulation of bone growth with thrombin peptide derivatives
05/17/2005US6894021 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
05/17/2005US6893869 For treatment of cancer/tumors/fungal/viral infections; tumor associated antigens; genetic engineering
05/17/2005US6893858 Human kcnq5 potassium channel, methods and compositions thereof
05/17/2005US6893838 DADD, death activator death domain protein
05/17/2005US6893833 Use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes
05/17/2005US6893662 Comprises methacrylic acid-methyl methacrylate copolymer layers for drug delivery to gastrointestinal tract
05/17/2005US6893656 Athletic patch
05/17/2005US6893651 Synergistic combination of cyclic ketoenol with agonists or antagonists of nicotinic acetylcholine receptors; protecting plants
05/17/2005US6893633 Methods and compositions for promoting the maturation of monocytes
05/17/2005US6893628 Aerosol formulations containing P134a and particulate medicament
05/17/2005US6893627 Method for treating type 2 diabetes with an extract of Artemisia
05/17/2005CA2402712C Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease
05/17/2005CA2301548C Azetidinone derivatives for the treatment of hcmv infections
05/12/2005WO2005043159A1 Water-soluble compound
05/12/2005WO2005043155A1 System and method for the treatment of cancer, including cancers of the central nervous system
05/12/2005WO2005042727A2 Methods of organ regeneration
05/12/2005WO2005042714A2 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
05/12/2005WO2005042486A1 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
05/12/2005WO2005042048A2 Bioactive hydrogel compositions for regenerating connective tissue
05/12/2005WO2005042030A1 Treatment of proliferative diseases using an antisense iap oligomer and chemotherapeutic agent
05/12/2005WO2005042022A2 Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
05/12/2005WO2005042021A2 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
05/12/2005WO2005042020A2 Combinations for hcv treatment
05/12/2005WO2005042013A1 Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals
05/12/2005WO2005042003A1 Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
05/12/2005WO2005042002A2 Treatment of rhematoid arthritis with flip antagonists
05/12/2005WO2005041999A1 Composition to enhance joint function and repair
05/12/2005WO2005041984A1 Compositions and treatments for envelope virus infections
05/12/2005WO2005041979A1 Modulation of microglial by nicotinic medications
05/12/2005WO2005041975A1 Use of bh4 for the treatment of respiratory diseases
05/12/2005WO2005041969A1 Pharmaceutical product comprising a beta-2 adrenergic agonist and an h1-receptor antagonist
05/12/2005WO2005041962A1 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
05/12/2005WO2005041960A2 Neuromuscular blocking agents and antagonists thereof
05/12/2005WO2005041956A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
05/12/2005WO2005041944A2 Methods and compositions for promoting axon regeneration and cell replacement therapy
05/12/2005WO2005041919A2 Medicamentously targeted local lipolysis
05/12/2005WO2005041865A2 Compounds and method for treating cancer
05/12/2005WO2005041657A1 Zeolite molecular sieves for the removal of toxins
05/12/2005WO2005023368B1 Prophylaxis of and treatment for infections from the family chlamydiaceae using amino acids as leucine or methionine
05/12/2005WO2005000270A3 Inhalable formulations for treating pulmonary hypertension and methods of using same
05/12/2005WO2004105682A3 Carbostyril derivatives and mood stabilizers for treating mood disorders
05/12/2005WO2004103311A3 Antibiotic composition
05/12/2005WO2004084828A3 Keratinocyte-fibrocyte concomitant grafting for wound healing
05/12/2005WO2004082715A8 Concomitant drug as therapeutic agent for inflammatory bowel disease
05/12/2005WO2004080414A3 Composition and method for treating inflammations by reducing c-reactive protein
05/12/2005WO2004071391A3 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders
05/12/2005WO2004000858A3 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
05/12/2005WO2001079525A3 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
05/12/2005US20050101691 Anti-microbial tool grip
05/12/2005US20050101674 PPMP as a ceramide catabolism inhibitor for cancer treatment
05/12/2005US20050101671 Compounds and compositions for delivering active agents
05/12/2005US20050101664 Anionically coupling an acyl imidazoyl carbamate with a primary amide or carbamate; N-alkylation; inosine-5*-monophosphate dehydrogenase inhibitors
05/12/2005US20050101662 Such as coumarin, dicoumarol, 7-hydroxycoumarin (umbelliferone), 6,7- dihydroxycoumarin (exculetin), 3,6,7 trihydroxycoumarin, warfarin, or warfarin sodium; cancer, Alzheimer's disease, gout, atherosclerosis, restenosis
05/12/2005US20050101658 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
05/12/2005US20050101657 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative
05/12/2005US20050101655 Migraine treatments including isovaleramide compounds and serotonin agonists
05/12/2005US20050101653 Combination therapy for the treatment of migraine
05/12/2005US20050101652 New salt hydrates
05/12/2005US20050101640 Synergistic mixture; hypotensive agents; dosage control
05/12/2005US20050101635 Delivering to an external portion of the body passageway of a patient in need of a therapeutically effective amount of an antihistamine or decongestant to treat inflammatory diseases
05/12/2005US20050101632 Treating inflammation of the skin or mucous membrane by topical administration of an anti-inflammatory amount of dimethicone in the absence of any other anti-inflammatory agent
05/12/2005US20050101618 Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
05/12/2005US20050101611 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
05/12/2005US20050101608 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
05/12/2005US20050101607 Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor
05/12/2005US20050101605 with a hydrophilic nonionic polyol surfactant; for gastrointestinal administration; storage stable with little methyl folic acid formed; glycerin, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, sodium saccarin
05/12/2005US20050101594 Compositions useful as inhibitors of protein kinases
05/12/2005US20050101579 Endometriosis treatment protocol
1 ... 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 ... 1151